These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1520915)

  • 1. Antithrombotic and thrombolytic activity of sulodexide in rats.
    Barbanti M; Guizzardi S; Calanni F; Marchi E; Babbini M
    Int J Clin Lab Res; 1992; 22(3):179-84. PubMed ID: 1520915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism.
    Barbanti M; Calanni F; Milani MR; Marchi E; Semeraro N; Colucci M
    Thromb Haemost; 1993 Feb; 69(2):147-51. PubMed ID: 8456427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats.
    Andriuoli G; Mastacchi R; Barbanti M
    Thromb Res; 1984 Apr; 34(1):81-6. PubMed ID: 6729771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B; Fareed J
    Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desmin 370, a low molecular weight dermatan sulfate, reduces the weight of preformed thrombi in rats made afibrinogenemic by ancrod.
    Barbanti M; Calanni F; Marchi E; Semeraro N; Colucci M
    Thromb Haemost; 1995 Feb; 73(2):287-90. PubMed ID: 7792745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic and thrombolytic effects of galactan polysulfate (DH 6322) in rats.
    Kumada T; Inoue K; Korenaga H; Abiko Y
    Thromb Res; 1985 Jul; 39(1):21-8. PubMed ID: 4035647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide.
    Ceriello A; Quatraro A; Marchi E; Barbanti M; Giugliano D
    Diabete Metab; 1993; 19(2):225-9. PubMed ID: 8339853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulodexide may alleviate neointimal hyperplasia by inhibiting angiopoietin‑2 in an arteriovenous fistula model.
    Lei Y; Zheng Z; Wang Y; Liu Y; Liu R; Xu Q; Yu X
    Mol Med Rep; 2013 Mar; 7(3):831-5. PubMed ID: 23358592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction.
    Condorelli M; Chiariello M; Dagianti A; Penco M; Dalla Volta S; Pengo V; Schivazappa L; Mattioli G; Mattioli AV; Brusoni B
    J Am Coll Cardiol; 1994 Jan; 23(1):27-34. PubMed ID: 8277091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulodexide in the treatment of chronic venous disease.
    Andreozzi GM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):73-81. PubMed ID: 22329592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defibrotide is antithrombotic and thrombolytic against rabbit venous thrombosis.
    Niada R; Pescador R; Porta R; Mantovani M; Prino G
    Haemostasis; 1986; 16 Suppl 1():3-8. PubMed ID: 3519381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TFC-612, a prostaglandin E1 derivative, enhances fibrinolytic activity in rats.
    Motoyama Y; Sakata Y; Seki J; Sato M; Namikawa Y; Horiai H; Ono T
    Thromb Res; 1992 Jan; 65(1):55-63. PubMed ID: 1604443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis.
    Bernat A; Vallée E; Maffrand JP; Roncucci R
    Thromb Res; 1985 Jan; 37(2):279-85. PubMed ID: 3975872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation.
    Mauro M; Palmieri GC; Palazzini E; Barbanti M; Calanni Rindina F; Milani MR
    Curr Med Res Opin; 1993; 13(2):87-95. PubMed ID: 8325046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic activity of defibrotide: a morphometric evaluation in experimental venous thrombosis.
    Fumagalli G; Sala C; Angelaccio E; Lombardo N; Clementi F
    Pharmacol Res; 1989; 21(3):293-8. PubMed ID: 2748512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recruitment of labelled monocytes by experimental venous thrombi.
    McGuinness CL; Humphries J; Waltham M; Burnand KG; Collins M; Smith A
    Thromb Haemost; 2001 Jun; 85(6):1018-24. PubMed ID: 11434678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulodexide: a renewed interest in this glycosaminoglycan.
    Lauver DA; Lucchesi BR
    Cardiovasc Drug Rev; 2006; 24(3-4):214-26. PubMed ID: 17214598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans.
    Vogel GM; Meuleman DG; Bourgondiën FG; Hobbelen PM
    Thromb Res; 1989 Jun; 54(5):399-410. PubMed ID: 2549654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
    Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.